1. Pink Sheet
  2. >>Market Access

Brilinta Value-Based Contract With UPMC Incorporates Two-Sided Risk

 
• By Jessica Merrill

AstraZeneca and UPMC Health Plan have signed a value-based contract for Brilinta linked to cardiovascular outcomes, with UPMC agreeing to pay more if the drug outperforms expectations.  

Risk Management Word RISK on Unstable Stack of Gold Coins - Image

AstraZeneca PLC and UPMC Health Plan have signed a novel value-based reimbursement contract for the blood thinner Brilinta (ticagrelor) that shares risk on both sides: UPMC agrees to pay more if Brilinta outperforms expectations and AstraZeneca agrees to pay a bigger rebate if it under-performs. AstraZeneca and UPMC believe it is one of the first value-based contract of its kind to incorporate two-sided risk.

"AstraZeneca pays significantly more rebate to UPMC if the drug doesn't work, as outlined by criteria within the contract. On...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

China Unveils Multiple Policies To Support Innovative Drugs Throughout Life Cycle

 
• By Xu Hu

China has announced a raft of new measures to encourage innovative drug development across the product life cycle, including using insurance data to differentiate new therapies and applying commercial insurance to selected novel products.

Medicaid Changes Could Have Major Impact on Recent Coverage Improvements

 
• By Tim Casey

Insurance trade groups warned that the Big Beautiful Bill destabilize Medicaid and result in the largest ever roll-back in health care coverage in the US.

England’s NHS Plan Eyes Cancer Vaccine Boost, Single Formulary & ‘Pay For Impact’ Drug Deal

 
• By Eliza Slawther

The creation of a single national formulary for medicines prescribing that could impact industry is among the action points in the UK government’s new 10-year health plan for the National Health Service in England.

Here At Last: Canada’s Long-Contested Guidelines For Curbing Excessive Drug Prices

 
• By Neena Brizmohun

Final guidelines explaining how staff at Canada’s Patented Medicine Prices Review Board should go about identifying drugs that could be considered for an excessive price hearing will come into force soon.

More from Pink Sheet

Opuni Appointed Acting CEO Of Ghana’s FDA As Darko Leaves To Lead African Medicines Agency

 
• By Anabel Costa-Ferreira

Kwabena Frimpong-Manso Opuni has been appointed as the new acting CEO of the Ghana Food and Drugs Authority, succeeding Delese Darko, who is now head of the Africa’s pan-continental medicines agency.

UK HRA Working On ‘Trusted’ Path Forward To Support Simplified Informed Consent

 
• By Vibha Sharma

The Health Research Authority is working on a streamlined model for informed consent that maintains people’s trust.

EU Ups Ante On Stockpiling For Crises

 
• By Francesca Bruce

The European Commission has published two new strategies on stockpiling that will improve the availability of critical medicines in times of crisis and reduce the EU’s dependance on suppliers outside the bloc.